Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

NCT01132690 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01132690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01132690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2010
Completion date
July 31, 2012
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease